BioLineRx Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	7.91	10.44	4.26	10.59	12.99	16.83
Short-Term Investments	17.3	9.13	38.74	40.5	44.15	5.76
Cash & Short-Term Investments	25.21	19.56	42.99	51.08	57.14	22.59
Cash Growth	-13.58%	-54.50%	-15.83%	-10.59%	152.95%	-17.83%
Accounts Receivable	-	2.48	0.36	-	-	-
Other Receivables	0.7	1.48	0.83	0.72	0.14	0.14
Total Trade Receivables	0.7	3.95	1.19	0.72	0.14	0.14
Inventory	2.18	3.15	1.95	-	-	-
Other Current Assets	0.43	0.44	1.05	0.2	0.13	0.15
Total Current Assets	28.52	27.1	47.18	52	57.4	22.88
Net Property, Plant & Equipment	0.89	1.35	1.89	2.5	2.28	2.7
Other Intangible Assets	10.39	10.45	14.85	21.89	21.7	21.71
Total Assets	39.8	38.91	63.93	76.38	81.39	47.29
Accounts Payable	3.54	5.58	10.87	6.97	5.57	5.92
Accrued Expenses	2.13	3.13	3.35	1.74	1.23	1.44
Current Portion of Long-Term Debt	4.48	4.48	3.15	1.54	2.76	3.09
Current Portion of Leases	0.3	0.52	0.53	0.43	0.17	0.19
Unearned Revenue	-	-	12.96	-	-	-
Other Current Liabilities	3.23	1.69	11.93	-	-	-
Total Current Liabilities	13.67	15.41	42.78	10.68	9.72	10.64
Long-Term Debt	5.6	8.96	6.63	8.63	-	2.74
Long-Term Leases	1	1.08	1.29	1.73	1.73	1.66
Other Long-Term Liabilities	-	-	-	4.51	1.86	10.22
Total Long-Term Liabilities	6.6	10.04	7.92	14.86	3.59	14.62
Total Liabilities	20.27	25.45	50.7	25.54	13.3	25.26
Common Stock	73.43	38.1	31.36	27.1	21.07	9.87
Additional Paid-in Capital	347.14	376.61	373.89	355.15	353.48	291.56
Accumulated Other Comprehensive Income	-1.42	-1.42	-1.42	-1.42	-1.42	-1.42
Retained Earnings	-399.62	-399.83	-390.61	-329.99	-305.04	-277.99
Shareholders' Equity	19.53	13.46	13.22	50.84	68.09	22.03
Total Liabilities & Equity	39.8	38.91	63.93	76.38	81.39	47.29
Total Debt	11.38	15.04	11.59	12.32	4.65	7.68
Net Cash (Debt)	13.83	4.52	31.4	38.76	52.48	14.9
Net Cash Growth	205.93%	-85.60%	-18.98%	-26.15%	252.17%	-12.51%
Net Cash Per Share	-	2.27	19.56	30.05	47.50	35.37
Book Value	19.53	13.46	13.22	50.84	68.09	22.03
Book Value Per Share	-	6.74	8.24	39.41	61.62	52.28
Tangible Book Value	9.15	3.01	-1.63	28.96	46.38	0.32
Tangible Book Value Per Share	-	1.51	-1.02	22.45	41.98	0.75

Updated Nov 24, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q